Specify a stock or a cryptocurrency in the search bar to get a summary
Hyloris Developmentsen Sa
52UHyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium. Address: Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000
Analytics
WallStreet Target Price
17.22 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 52U
Dividend Analytics 52U
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 52U
Stock Valuation 52U
Financials 52U
Results | 2019 | Dynamics |